EATG » EU policy

EU policy

About half of clinical trials go unreported in EU

Pharma companies are more compliant in posting results compared to universities. Approximately half of all clinical trials registered in the European Union have not reported results on the European Union…

CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests

On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation (EC) No 469/2009 concerning the supplementary protection…

Half of Europe’s clinical trials fail to report results despite EU rule

LONDON, September 13, 2018 - Almost half of all European-registered clinical trials - in which scientists test drug treatments, interventions or therapies in humans - have breached EU rules by failing…

Sexual Health & HIV Policy EUROBulletin, August 2018 issue

The Sexual Health & HIV Policy EUROBulletin, August 2018 issue is now available online. The bulletin is published quarterly and aims to provide information about policies, programmes, standards, guidance, evidence…

Open letter: UN General Assembly High Level Meeting on the fight against Tuberculosis

Few weeks before the UN General Assembly High Level Meeting on the fight against Tuberculosis, the EATG issues an open letter: 'As negotiations on the final declaration are now being…

Highest-risk groups left behind in pursuit of viral hepatitis C elimination in Europe

Brussels, 27 July 2018 – The European Liver Patients’ Association (ELPA) annual update on the state of viral hepatitis C (HCV) policy in Europe shows that many European countries have yet…

The EATG welcomes the European Court of Justice decision to invalidate the patent extension of Truvada

Amsterdam, 26 July 2018   The European AIDS Treatment Group welcomes the landmark decision of the European Court of Justice confirming the invalidity of the patent extension (Supplementary Protection Certificate)…

How to ensure access to essential medicines for all? New WHO report reviews medicines reimbursement policies in Europe

The new WHO report “Medicines reimbursement policies in Europe” examines the various policies that increase access to affordable medicines. Based on direct data collection from 45 of the 53 countries…

How patents, data exclusivity and SPCs interact to extend market exclusivity of medicines: the example of Truvada

Patents usually confer 20-year exclusive rights on inventions. Data exclusivity laws confer, depending on the country, 5 to 10 years’ exclusive rights over safety and efficacy data submitted for the…

Belgium and the Netherlands achieve first successful joint drug price

Beneluxa Initiative partners Belgium and the Netherlands successfully negotiated the price of Spinraza Belgium and the Netherlands have reached an agreement on the pricing of Spinraza, a drug for Spinal…

1 2 3 10